Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 1
2014 1
2015 2
2016 1
2017 1
2018 1
2019 1
2020 2
2021 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 5 Anorexia, CTCAE"
Page 1
Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Holyoake DLP, Warren DR, Hurt C, Aznar M, Partridge M, Mukherjee S, Hawkins MA. Holyoake DLP, et al. Clin Oncol (R Coll Radiol). 2018 Jul;30(7):418-426. doi: 10.1016/j.clon.2018.02.067. Epub 2018 Mar 28. Clin Oncol (R Coll Radiol). 2018. PMID: 29602584 Clinical Trial.
The independent variables analysed comprised age, sex, performance status, baseline symptoms, tumour size, weight loss, chemotherapy regimen and dose-volume histogram of stomach and duodenum in 5 Gy bins. The outcome measures used were Common Terminology Criteria of Advers …
The independent variables analysed comprised age, sex, performance status, baseline symptoms, tumour size, weight loss, chemotherapy regimen …
The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer.
Dreyfuss AD, Barsky AR, Wileyto EP, Eads JR, Kucharczuk JC, Williams NN, Karasic TB, Metz JM, Ben-Josef E, Plastaras JP, Wojcieszynski AP. Dreyfuss AD, et al. Cancer Med. 2021 Feb;10(4):1275-1288. doi: 10.1002/cam4.3724. Epub 2021 Jan 20. Cancer Med. 2021. PMID: 33474812 Free PMC article.
Descriptive statistics were used to report disease-control outcomes and CTCAE v4.0-5.0 toxicities. Univariable and multivariable Cox regression, and stepwise regression were used to identify associations with survival. ...Most common acute grade 3 toxicities …
Descriptive statistics were used to report disease-control outcomes and CTCAE v4.0-5.0 toxicities. Univariable and multivariab …
A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V, Abraham G, Patil V, Joshi A, Menon N, Mahajan A, Janu A, Jain S, Talreja VT, Kapoor A, Kumar Singh G, Khaddar S, Gupta K, Rathinasamy N, Srinivas S, Agrawal A, Ventrapati P, Prabhash K. Noronha V, et al. Cancer Med. 2021 Mar;10(5):1525-1534. doi: 10.1002/cam4.3617. Epub 2021 Feb 16. Cancer Med. 2021. PMID: 33591635 Free PMC article.
METHODS: This was a single center retrospective analysis of prospective data base of patients with non-melanoma solid tumors who were treated with immunotherapy from August 2015 to November 2018. Adverse events during immunotherapy were documented and graded using CTCAE …
METHODS: This was a single center retrospective analysis of prospective data base of patients with non-melanoma solid tumors who were treate …
Continuous hyperfractionated accelerated radiotherapy - Escalated dose (CHART-ED): A phase I study.
Hatton MQ, Hill R, Fenwick JD, Morgan SA, Wilson PC, Atherton PJ, Dickson J, Murray KE, Paul J. Hatton MQ, et al. Radiother Oncol. 2016 Mar;118(3):471-7. doi: 10.1016/j.radonc.2015.11.015. Epub 2015 Dec 11. Radiother Oncol. 2016. PMID: 26687902 Free article. Clinical Trial.
RESULTS: Between April 2010 and May 2012, 18 patients were enrolled from 5 UK centres and received escalated dose radiotherapy. 14 were male, 16 squamous cell histology and 12 were stage IIIA or IIIB. ...Of these 9 patients have died to date with a median survival of 2 yea …
RESULTS: Between April 2010 and May 2012, 18 patients were enrolled from 5 UK centres and received escalated dose radiotherapy. 14 we …
Adverse drug events and contributing factors among pediatric cancer patients at Jimma University medical center, Southwest Ethiopia.
Tola WO, Melaku T, Fufa D, Sheleme T. Tola WO, et al. BMC Pediatr. 2023 Feb 13;23(1):77. doi: 10.1186/s12887-023-03891-9. BMC Pediatr. 2023. PMID: 36782170 Free PMC article.
The most common ADEs were hematologic toxicities (anemia 55(11.8%), neutropenia 52(11.16%) & thrombocytopenia 31(6.65%)), and gastrointestinal effects (nausea 46(9.87%), vomiting 46(9.87%), anorexia 41(8.8%). Out of 466 ADEs, 150 (32.19%) were classified as common term …
The most common ADEs were hematologic toxicities (anemia 55(11.8%), neutropenia 52(11.16%) & thrombocytopenia 31(6.65%)), and gastrointe …
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.
Komrokji RS, Padron E, Yu D, Fulp WJ, Rodriguez Y, Tinsley S, List AF, Lancet JE. Komrokji RS, et al. Am J Hematol. 2014 Aug;89(8):809-12. doi: 10.1002/ajh.23749. Epub 2014 May 16. Am J Hematol. 2014. PMID: 24764152 Free PMC article. Clinical Trial.
Four deaths occurred on study (sepsis, intracranial hemorrhage, sudden death, and acute myeloid leukemia (AML)). The most common observed grade 3/4 toxicities according to CTCAE v3 were diarrhea (17.1%), rash (17.1%), and infection (11.6%), accompanied by fatigue, t …
Four deaths occurred on study (sepsis, intracranial hemorrhage, sudden death, and acute myeloid leukemia (AML)). The most common observed …
Evaluation of interobserver and interscale agreement in assessing late bowel toxicity after pelvic radiation in patients with carcinoma of the cervix.
Chinnachamy AN, Chopra S, Krishnatry R, Kannan S, Thomas B, Mahantshetty U, Engineer R, Shrivastava SK. Chinnachamy AN, et al. Jpn J Clin Oncol. 2013 May;43(5):508-14. doi: 10.1093/jjco/hyt028. Epub 2013 Mar 20. Jpn J Clin Oncol. 2013. PMID: 23515269
Amongst these, grade 1, 2 and 3 toxicity was observed in 6, 5 and 1 patient, respectively. ...CONCLUSIONS: High interobserver agreement was observed for both RTOG and most CTCAE subscales; most disagreements were for grade 1-2. Interscale agreement (RT …
Amongst these, grade 1, 2 and 3 toxicity was observed in 6, 5 and 1 patient, respectively. ...CONCLUSIONS: High interobserver …
Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
Kong L, Zhang YW, Hu CS, Guo Y. Kong L, et al. Chin J Cancer. 2010 May;29(5):551-5. doi: 10.5732/cjc.009.10518. Chin J Cancer. 2010. PMID: 20426907 Free article. Clinical Trial.
The latest version of the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE 3.0) was used for grading all adverse events. RESULTS: Fifty nine patients were evaluable for treatment response. ...The rates of grade 3/4 myelosu …
The latest version of the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE 3.0) was used for …
Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.
Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M. Yuki S, et al. Cancer Chemother Pharmacol. 2020 Jan;85(1):217-223. doi: 10.1007/s00280-019-03991-3. Epub 2019 Nov 25. Cancer Chemother Pharmacol. 2020. PMID: 31768696 Clinical Trial.
Median Time to treatment failure (TTF), Progression-free survival (PFS) and Overall survival (OS) was 5.7 (95% CI 4.6-7.0), 7.0 (95% CI 5.5-14.1), and 27.6 (95% CI 15.6-Not reached) months, respectively. Incidences of grade 3-4 adverse events > 10% …
Median Time to treatment failure (TTF), Progression-free survival (PFS) and Overall survival (OS) was 5.7 (95% CI 4.6-7.0), 7.0 (95% …
A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Okano K, Suto H, Oshima M, Maeda E, Yamamoto N, Kakinoki K, Kamada H, Masaki T, Takahashi S, Shibata T, Suzuki Y. Okano K, et al. Ann Surg Oncol. 2017 Sep;24(9):2777-2784. doi: 10.1245/s10434-017-5921-4. Epub 2017 Jun 12. Ann Surg Oncol. 2017. PMID: 28608121 Clinical Trial.
Seven patients failed to complete S-1 due to cholangitis (n = 5) or neutropenia (n = 2). The most common grade 3 toxicities [Common Terminology Criteria for Adverse Events (CTCAE) version 4.0] were anorexia (7%), nausea (5%), neutropenia (4%), a …
Seven patients failed to complete S-1 due to cholangitis (n = 5) or neutropenia (n = 2). The most common grade 3 toxicities [C …
12 results